highly significantP < 0.001
A subgroup analysis of the number of ADR reports finally revealed that the increment in ADR-reporting was solely and highly significant (P < 0.001) related to ADRs of non CAM drugs.
A subgroup analysis of the number of ADR reports finally revealed that the increment in ADR-reporting was solely and highly significant (P < 0.001) related to ADRs of non CAM drugs.